Aruj Ali, OD
Optometry · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Peninsula Laser Eye Medical Group Inc · 4 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ali’s office at (650) 961-2585 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$157,998
Medicare paid this office $157,998 for 611 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Placement of amniotic membrane on eye surface for wound healing | 59 | $81,729 | $973 |
| Established patient complete exam of visual system | 269 | $26,323 | $96 |
| Return visit (30+ min) | 104 | $10,329 | $90 |
| Short return visit (20+ min) | 105 | $9,696 | $71 |
| Exam of visual field with extended testing | 133 | $7,520 | $50 |
See all 11 services
| Placement of amniotic membrane on eye surface for wound healing | 59 | $81,729 | $973 |
| Established patient complete exam of visual system | 269 | $26,323 | $96 |
| Return visit (30+ min) | 104 | $10,329 | $90 |
| Short return visit (20+ min) | 105 | $9,696 | $71 |
| Exam of visual field with extended testing | 133 | $7,520 | $50 |
| Imaging of retina | 207 | $6,947 | $32 |
| Imaging of optic nerve | 125 | $3,527 | $25 |
| New patient visit (45+ min) | 31 | $3,349 | $108 |
| Photography of the retina | 105 | $3,308 | $30 |
| New patient complete exam of visual system | 27 | $2,815 | $104 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 71 | $835 | $11 |
Who their Medicare patients are
611 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 21% · Women 64% · Also on Medicaid 11% · Health risk score 1.16. Above the middle of the specialty; the typical optometry clinician is at 0.97.
Conditions among them: High blood pressure 73% · Diabetes 32% · Chronic kidney disease 25% · Coronary heart disease 22% · Depression 18% · Cancer 17% · Atrial fibrillation 15% · COPD 14% · Heart failure 13% · Dementia 6% · Stroke 6%.
The office billed $307,085, Medicare allowed $211,874 and paid $157,998; for 1,395 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 611 | 1,395 | 77 | 1.16 | $307,085 | $157,998 |
| 2023 | 517 | 985 | 78 | 1.07 | $178,325 | $89,691 |
| 2022 | 150 | 248 | 77 | 1.02 | $43,885 | $24,226 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Placement of amniotic membrane on eye surface for wound healing | 25 | $33,730 | $1,163 |
| Established patient complete exam of visual system | 159 | $14,324 | $90 |
| Return visit (30+ min) | 159 | $14,148 | $81 |
| Short return visit (20+ min) | 78 | $7,160 | $69 |
| Exam of visual field with extended testing | 106 | $5,186 | $43 |
| Imaging of retina | 153 | $4,679 | $30 |
| Imaging of optic nerve | 105 | $3,035 | $25 |
| New patient visit (45+ min) | 28 | $2,898 | $103 |
| New patient complete exam of visual system | 22 | $2,073 | $94 |
| Photography of the retina | 37 | $1,091 | $29 |
2022: 8 services
| Return visit (30+ min) | 45 | $4,444 | $99 |
| Established patient complete exam of visual system | 37 | $3,905 | $103 |
| Short return visit (20+ min) | 25 | $2,632 | $75 |
| New patient visit (45+ min) | 15 | $2,062 | $137 |
| New patient complete exam of visual system | 11 | $1,352 | $123 |
| Imaging of retina | 35 | $1,160 | $33 |
| Exam of visual field with extended testing | 19 | $950 | $50 |
| Imaging of optic nerve | 30 | $858 | $29 |
Drugs they prescribed that Part D paid
$116,832
Pharmacies billed $116,832 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 385) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
190 generic and 195 brand-name prescriptions · $116,832 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 16 | $21,175 | $1,323 |
| Cyclosporine | 32 | $19,426 | $607 |
| Xiidra | 11 | $17,184 | $1,562 |
| Restasis Multidose | 13 | $8,186 | $630 |
| Lumigan | 19 | $7,968 | $419 |
See all 11 drugs
| Restasis | 16 | $21,175 | $1,323 |
| Cyclosporine | 32 | $19,426 | $607 |
| Xiidra | 11 | $17,184 | $1,562 |
| Restasis Multidose | 13 | $8,186 | $630 |
| Lumigan | 19 | $7,968 | $419 |
| Latanoprost | 86 | $1,366 | $16 |
| Dorzolamide-Timolol | 51 | $1,167 | $23 |
| Prednisolone Acetate | 24 | $989 | $41 |
| Timolol Maleate | 25 | $291 | $12 |
| Brimonidine | 19 | $202 | $11 |
| Erythromycin | 11 | $137 | $12 |
Year by year
| 2024 | 385 | 171 | 0% (0) | 51% | $116,832 |
| 2023 | 223 | 117 | 0% (0) | 36% | $71,278 |
| 2022 | 14 | None | 0% (0) | None | $6,452 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Xiidra | 16 | $27,631 | $1,727 |
| Restasis | 12 | $21,042 | $1,753 |
| Cyclosporine | 12 | $12,353 | $1,029 |
| Dorzolamide-Timolol | 31 | $1,105 | $36 |
| Latanoprost | 25 | $737 | $29 |
| Prednisolone Acetate | 15 | $677 | $45 |
| Erythromycin | 34 | $403 | $12 |
| Timolol Maleate | 30 | $349 | $12 |
Money from drug and device companies
$2,098 in 2025
| 2025 | 7 | 31 | None | $2,098 |
| 2024 | 11 | 44 | None | $2,679 |
| 2023 | 11 | 38 | None | $2,747 |
| 2022 | 4 | 4 | None | $80 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotissue Holdings | None | $1,408 | 19 payments
|
| Alcon Vision | Tryptyr | $242 | 2 payments
|
| Bausch & Lomb Americas | Miebo | $155 | 5 payments
|
| Johnson & Johnson Vision Care | None | $135 | 1 payment
|
| CooperVision | Misight Contact Lens | $92 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $43 | 2 payments
|
See all 31 published payments
| CooperVision | Meals · 2025-11-09 | Misight Contact Lens | $92 |
| Bausch & Lomb Americas | Meals · 2025-10-29 | Miebo | $125 |
| Biotissue Holdings | Meals · 2025-10-07 | None | $41 |
| Biotissue Holdings | Meals · 2025-09-30 | None | $88 |
| Bausch & Lomb Americas | Meals · 2025-08-28 | Miebo | $7 |
| Bausch & Lomb Americas | Meals · 2025-08-28 | Miebo | $5 |
| Alcon Vision | Meals · 2025-07-15 | Tryptyr | $144 |
| Biotissue Holdings | Meals · 2025-07-11 | None | $143 |
| Biotissue Holdings | Meals · 2025-06-18 | None | $25 |
| Biotissue Holdings | Meals · 2025-06-10 | None | $25 |
| Tarsus Pharmaceuticals | Meals · 2025-06-02 | Xdemvy | $14 |
| Biotissue Holdings | Meals · 2025-05-29 | None | $125 |
| Biotissue Holdings | Meals · 2025-05-14 | None | $25 |
| Biotissue Holdings | Meals · 2025-04-22 | None | $10 |
| Biotissue Holdings | Meals · 2025-04-21 | None | $12 |
| Biotissue Holdings | Meals · 2025-04-16 | None | $44 |
| Biotissue Holdings | Meals · 2025-04-15 | None | $65 |
| Biotissue Holdings | Meals · 2025-04-03 | None | $94 |
| Biotissue Holdings | Meals · 2025-03-28 | None | $155 |
| Alcon Vision | Meals · 2025-03-27 | Precision7 | $99 |
| Biotissue Holdings | Meals · 2025-03-19 | None | $40 |
| Bausch & Lomb Americas | Meals · 2025-03-17 | Infuse | $7 |
| Johnson & Johnson Vision Care | Meals · 2025-03-05 | None | $135 |
| Biotissue Holdings | Meals · 2025-02-28 | None | $118 |
| Biotissue Holdings | Meals · 2025-02-21 | None | $91 |
| Bausch & Lomb Americas | Meals · 2025-02-18 | Vyzulta | $11 |
| Biotissue Holdings | Meals · 2025-02-06 | None | $147 |
| Biotissue Holdings | Meals · 2025-02-02 | None | $96 |
| Biotissue Holdings | Meals · 2025-02-02 | None | $64 |
| Tarsus Pharmaceuticals | Meals · 2025-01-13 | Xdemvy | $28 |
| Oyster Point Pharma | Meals · 2025-01-04 | Tyrvaya | $23 |
See earlier years (2024, 2023, 2022)
2024: $2,679
| Alcon Vision | Total30 | $1,550 | 7 payments
|
| Biotissue Holdings | None | $368 | 11 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $238 | 7 payments
|
| Bausch & Lomb Americas | Vyzulta | $220 | 8 payments
|
| RxSight | Rxsight Contact Lens | $87 | 1 payment
|
| Dompe US | Oxervate | $67 | 3 payments
|
| Oyster Point Pharma | Tyrvaya | $62 | 3 payments
|
| Harrow Eye | Vevye | $30 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $20 | 1 payment
|
| Glaukos | Ce-Marked Kxla System | $20 | 1 payment
|
| Abbvie | Lumigan | $18 | 1 payment
|
2023: $2,747
| Biotissue Holdings | Prokera | $1,577 | 9 payments
|
| Oyster Point Pharma | Tyrvaya | $260 | 8 payments
|
| AbbVie | Durysta | $191 | 4 payments
|
| Bausch & Lomb Americas | Miebo | $152 | 6 payments
|
| Alcon Vision | Clareon | $129 | 2 payments
|
| CooperVision | Cvi Contact Lens | $124 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $109 | 1 payment
|
| Apellis Pharmaceuticals | None | $93 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $60 | 2 payments
|
| Rayner Intraocular Lenses | Omidria | $30 | 1 payment
|
| RxSight | Rxsight Contact Lens | $22 | 1 payment
|
2022: $80
| Mallinckrodt Hospital Products | Acthar | $28 | 1 payment
|
| Dompe US | Oxervate | $19 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $17 | 1 payment
|
| BioTissue Holdings | Prokera | $16 | 1 payment
|
Professional record
- NPI
- 1265174254
- Licence
- CA OPT35224
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 3803 S Bascom Ave Ste 104, Campbell, CA, 95008
- NPI first listed
- 2022-04-10
- NPI last updated
- 2026-08-20
- NPI record certified
- 2026-08-20
This is when the NPI record was last certified, not a medical board exam.